Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "NSE-filing"

7 News Found

Zydus Lifesciences acquires France-based FBC Medical through subsidiary Amplitude SAS
Biopharma | May 04, 2026

Zydus Lifesciences acquires France-based FBC Medical through subsidiary Amplitude SAS

Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs


Alkem Laboratories receives 7 observations following US FDA inspection at Daman facility
Drug Approval | May 04, 2026

Alkem Laboratories receives 7 observations following US FDA inspection at Daman facility

The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026


Aurobindo arm CuraTeQ receives Health Canada approval for bevacizumab biosimilar Bevqolva
Drug Approval | May 04, 2026

Aurobindo arm CuraTeQ receives Health Canada approval for bevacizumab biosimilar Bevqolva

Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market


Aster DM Healthcare invests Rs 96 crore to add 159-bed specialised Aster Women & Children centre in Bengaluru
Hospitals | April 14, 2026

Aster DM Healthcare invests Rs 96 crore to add 159-bed specialised Aster Women & Children centre in Bengaluru

With the expansion, the hospital’s total bed capacity will rise from 380 to 539 beds


Unichem’s US arm recalls Buspirone tablets after stability test OOS result
News | April 13, 2026

Unichem’s US arm recalls Buspirone tablets after stability test OOS result

No adverse events reported; recall involves 5 mg 500-count bottles in the US market


Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7
News | April 08, 2026

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7

API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle


Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies
Biotech | April 04, 2026

Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies

Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy